Get the Stockscreener App
4.915
6.39%
0.295
Quantum Biopharma Ltd stock is traded at $4.915, with a volume of 10,584.
It is up +6.39% in the last 24 hours and up +6.85% over the past month.
Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.
See More
Previous Close:
$4.62
Open:
$4.6
24h Volume:
10,584
Relative Volume:
0.06
Market Cap:
$8.93M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-10.64%
1M Performance:
+6.85%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$4.60
$4.99
1-Week Range:
$4.00
$5.50
52-Week Range:
$3.50
$8.86
Quantum Biopharma Ltd Stock (QNTM) Company Profile
Quantum Biopharma Ltd Stock (QNTM) Latest News
Quantum BioPharma initiates phase 1 multiple sclerosis trial By Investing.com - Investing.com Canada
Quantum BioPharma sues CIBC and RBC seeking $700M in damages - MSN
Quantum BioPharma initiates phase 1 multiple sclerosis trial - Investing.com
Quantum Biopharma Announces that Sentinel Dosing has Started for the Phase-1 Multiple Ascending Dose Clinical Trial for Lucid-21-302 (Lucid-Ms) in Australia - AccessWire
InvestmentPitch Media Video Discusses FSD Pharma's New OTCQB Symbol and Appointment of Former U.S. Congressman Stephen Buyer to its Board of DirectorsVideo Available on Investmentpitch.com - Marketscreener.com
Christian Attar Files Market Manipulation Case On Behalf of Quantum Biopharma - Marketscreener.com
Freedman Normand Friedland Files Market Manipulation Case On Behalf of Quantum Biopharma - PR Newswire
Quantum BioPharma Ltd - Stockhouse Publishing
FSD Pharma Signs Agreement with Covar Pharmaceuticals to Support the Development of Lucid-PSYCH - Marketscreener.com
Quantum Biopharma (NASDAQ:QNTM) Posts Link on Its Website to Access the Filed Complaint Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spo - AccessWire
Quantum BioPharma alleges major market manipulation By Investing.com - Investing.com Australia
Quantum BioPharma sues over alleged stock spoofing - The Globe and Mail
Quantum BioPharma sues CIBC and RBC seeking $700M in damages | 2024-10-21 | Investing News - Stockhouse Publishing
Quantum BioPharma alleges major market manipulation - Investing.com
Quantum BioPharma (Nasdaq: QNTM) Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing - Chronicle-Tribune
Quantum BioPharma (QNTM) Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700M - StreetInsider.com
Quantum BioPharma Ltd. (NASDAQ: QNTM): Pioneering Alcohol Metabolism Support with Unbuzzd - openPR
Kairos Pharma (NYSEAmerican: KAPA): Advancing New Strategies to Overcome Cancer Treatment Challenges - openPR
Quantum BioPharma Expands Market for Alcohol Metabolism Product Unbuzzd - Vancity Buzz
Celly Nu secures distribution for alcohol metabolism drink By Investing.com - Investing.com South Africa
Celly Nu secures distribution deal in the Caribbean By Investing.com - Investing.com South Africa
Celly Nu secures distribution deal in the Caribbean - Investing.com India
Celly Nu secures distribution for alcohol metabolism drink - Investing.com
Quantum BioPharma Ltd. Provides Update from Celly Nutrition Signing a Master Distribution Agreement with FUSION Distribution Group across Puerto Rico, The Caribbean, and Parts of Central and South America - Newsfile
Quantum BioPharma Ltd. Pharma Provides Update from Celly Nutrition Signing a Master Distribution Agreement with FUSION Distribution Group Across Puerto Rico, the Caribbean, and Parts of Central and South America - WSIL TV
Quantum BioPharma Ltd. Provides Update from Celly Nutrition Signing a Master Distribution Agreement with FUSION Distribution Group across Puerto Rico, The Caribbean, and parts of Central and South America - AccessWire
Pre-market Movers: ALZN, VRAX, APDN, LQDA... - RTTNews
Quantum Biopharma Provides Corporate Update - GuruFocus.com
Quantum BioPharma to Present at Global Growth and Investment Conference Presented by ArcStone Securities and Investments and Kingswood US - Markets Insider
Quantum BioPharma to Present at Global Growth and Investment Conference Presented by ArcStone Securities and Invesments and Kingswood US - Quantisnow
Investor.News Prepares for the ArcStone-Kingswood Growth Summit 2024 - InvestorNews Inc.
Quantum BioPharma Closes Private Placement Offering - Invezz
QUANTUM BIOPHAR (QNTM) Upgraded to Buy: Here's What You Should Know - MSN
Quantum BioPharma Ltd. announced that it has received CAD 0.000036 million in funding from Fortius Research and Trading Corporation, Xorax Family Trust - Marketscreener.com
Quantum BioPharma to run multiple sclerosis progression study | 2024-09-09 | Investing News - Stockhouse Publishing
Quantum BioPharma partners for multiple sclerosis study - Investing.com
S&P 500 Materials [Sector] (SRMA) QuotePress Release - The Globe and Mail
Quantum Biopharma Signs an Agreement With Ingenu CRO to Conduct a Clinical Study to Observe Disease Progression in Patients With Primary Progressive Multiple Sclerosis - Digital Journal
Quantum Biopharma Signs an Agreement With Ingenu CRO to Conduct a Clinical Study to Observe Disease - PharmiWeb.com
The Globe and Mail - The Globe and Mail
ArcanaBio Secures Funding from BioInnovation Institute to Revolutionize Healthcare with new Ultra-Rapid Liquid Biopsy Technology - Via Ritzau
Quantum Biopharma Receives Nasdaq Notification of Regaining Compliance with Nasdaq's Minimum Bid Price Requirement and Completes Debt Settlements - AccessWire
Quantum Biopharma Ltd Stock (QNTM) Financials Data
There is no financial data for Quantum Biopharma Ltd (QNTM). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.16%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):